

DMD # 70052

Effects of chronic renal failure on brain cytochrome P450 in rats

**Judith Naud PhD, Jessica Harding MSc, Caroline Lamarche MD, Stephanie Beauchemin
MSc, Francois A. Leblond PhD and Vincent Pichette MD PhD**

Service de néphrologie et Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Faculté de
Médecine, Université de Montréal, Québec, Canada (J.N., J.H., C.L., S.B., F.A.L., V.P.)

Département de pharmacologie, Faculté de Médecine, Université de Montréal, Québec, Canada
(J.N., J.H., V.P.)

DMD # 70052

Brain CYP450 in renal failure

Correspondence should be addressed to: Vincent Pichette MD Ph.D.
Centre de recherche de l'hôpital Maisonneuve-
Rosemont
5415 boul. de l'Assomption, Montréal, Québec,
Canada
H1T 2M4
Tel: (514) 252-3489
Fax: (514) 255-3026
E-mail: vpichette.hmr@ssss.gouv.qc.ca

Number of text pages: 15

Number of tables: 3

Number of figures: 5

Number of references: 32

Number of words in Abstract: 248 words

Number of words in Introduction: 432 words

Number of word in Discussion: 867 words

List of non-standard abbreviations: CRF: chronic renal failure, CTL: control, CYP450: cytochrome P450, DFB: 3-[(3,4-difluorobenzyl)oxy]-5,5-dimethyl-4-[4-methylsulfonyl]phenyl]furan-2(5H)-one, DFH: 3-hydroxy-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]furan-2(5H)-one, PCR: polymerase chain reaction, PMSF: Phenylmethylsulfonyl fluoride, PTH: parathyroid hormone, PTH1R: parathyroid hormone receptor 1, PTH2R: parathyroid hormone receptor 2, PTX: parathyroidectomy, qPCR:

DMD # 70052

quantitative PCR

ABSTRACT

Chronic renal failure (CRF) impedes renal excretion of drugs, and their metabolism by reducing the expression of liver cytochrome P450 (CYP450). Uremic serum contains factors, such as parathyroid hormone (PTH), that decrease liver CYP450s. CYP450s are also involved in the metabolism of xenobiotics in the brain. This study investigates (1) the effects of CRF on rat brain CYP450, (2) the role of PTH in the downregulation of brain CYP450s in CRF rats, and (3) the effects of PTH on CYP450s in astrocytes. Protein and mRNA expression of CYP450s were assessed in the brain of CRF and control rats as well as from control or CRF rats that underwent parathyroidectomy (PTX) one week prior to nephrectomy. CYP3A activity was measured using 3-[(3, 4-difluorobenzyl) oxy]-5, 5-dimethyl-4-[4-methylsulfonyl] phenyl] furan-2(5H)-one metabolism in brain microsomal preparation. CYP3A protein expression was assessed in primary cultured astrocytes incubated with serum obtained from CRF or control rats, or with PTH. Significant downregulations ($\geq 40\%$) of CYP1A, CYP2C11 and CYP3A proteins were observed in microsomes from CRF rat brains. CYP3A activity reduction was also observed. CYP3A expression and activity were unaffected in PTX- pre-treated CRF rats. Serum of PTX-treated CRF rats had no impact on CYP3A levels in astrocytes compared to that of untreated CRF rats. Finally, PTH addition to normal calf serum induced a reduction in CYP3A protein similar to CRF serum suggesting that CRF induced hyperparathyroidism is associated with a significant decrease in CYP450 drug-metabolizing enzymes in the brain, which may have implications in drug response.

INTRODUCTION

Cytochrome P450 (CYP450) proteins are the major catalyst of phase I metabolism. They are involved in the oxidative metabolism of endogenous and exogenous substrates such as xenobiotics, cholesterol, steroids and vitamin D metabolism. CYP450 expression is highest in the liver, but can also be found in various organs including the intestine, the kidneys, the lungs and the brain.

Brain CYP450s are involved in the metabolism of xenobiotics, such as antidepressants, opiates, steroids and antipsychotics, as well as endobiotics, such as steroids, arachidonic acid, dopamine and serotonin (Miksys and Tyndale, 2013). CYP450 isoforms such as CYP1A1/2, CYP2B1, CYP2C11, CYP2D1-6, CYP2E1, CYP3A1 and CYP4F have been identified in rat brain (Morse et al., 1998; Imaoka et al., 2005; Yadav et al., 2006; Miksys and Tyndale, 2013). Although the overall expression of individual CYP450 in the brain is very low, very high activity of specific CYP450 enzymes can be found in different brain regions such as the hippocampus, the cerebellum, cortex and hypothalamus, where these proteins are suggested to participate in local endobiotic and xenobiotic metabolism (Miksys and Tyndale, 2002; Yadav et al., 2006; Meyer et al., 2007).

Over the past 15 years, many studies have demonstrated that chronic renal failure (CRF) significantly affects the expression and activity of liver, intestine and kidney CYP450, thus altering extra-renal drug metabolism (Leblond et al., 2000; Leblond et al., 2001; Leblond et al., 2002; Naud et al., 2011; Naud et al., 2012b) and vitamin D metabolism (Michaud et al., 2010). Parathyroid hormone (PTH) has been identified as a major factor responsible for the CYP450 downregulation in CRF rats (Michaud et al., 2006; Michaud et al., 2010). In light of these studies, we hypothesized that CRF could also impede brain CYP450 expression and/or activity, and that PTH could be involved in brain CYP450 modulation.

DMD # 70052

The objective of this study was thus to investigate the effect of CRF on CYP450s in whole or specific regions of rat brain, and the involvement of PTH in it. To address this, we have measured the protein and mRNA expression of CYP450s in cerebellum, cortex, hippocampus and remaining brain tissue from CRF and CTL rats. To assess the involvement of PTH, we measured the protein expression and the activity of CYP3A in microsomes purified from brains of CRF, parathyroidectomized-CRF (CRF-PTX), parathyroidectomized-control (CTL-PTX) and control rats. To investigate further the role of PTH, we measured the expression levels of CYP3A in primary rat astrocytes cultured in the presence of sera obtained from CTL, CRF, CRF-PTX and CTL-PTX rats. Finally, astrocytes were incubated with high concentration PTH, to evaluate the effect of PTH on CYP3A expression.

MATERIALS AND METHODS

Experimental model

Male Sprague-Dawley rats (Charles River, Portage, MI), weighing 176 to 225 g were housed in the Research Center animal care facility and maintained on Harlan Teklad rodent diet (Harlan Teklad Global Diets, Montreal, Canada) and water *ad libitum*. Animals were allowed an acclimatization period of at least 7 days before the first nephrectomy was performed. All the experiments were conducted according to the Canadian Council on Animal Care guidelines for care and use of laboratory animals and under the supervision of our local animal care committee.

Chronic renal failure was induced by two-stage 5/6 nephrectomy as described previously (Leblond et al., 2001). Rats from control group also underwent two sham laparotomies (day 1 and 8). Every animal had ad libitum access to water, but in order to limit the effects of CRF-induced malnutrition, control pair-fed rats were fed the same amount of chow that CRF rats ate on the previous day. At day 41 after the nephrectomy, the rats were housed in metabolic cages and urine was collected for 24 hours to determine the clearance of creatinine. Rats were sacrificed by decapitation at 42 days for brain and blood collection. Brain was immediately excised, rinsed in ice-cold saline then either dissected fractions (cerebellum, cortex, hippocampus and remaining brain parenchyma, n=12 CTL and 13 CRF) or whole brain (n=13 CTL, 8 CTL-PTX, 13 CRF, 11 CRF-PTX) were flash-frozen in liquid nitrogen. Samples were stored at -80°C until microsome preparation or mRNA extraction. After collection, blood was rapidly stored on ice. After coagulation, serum was recovered by centrifugation (600 g for 10 min at 4°C) and samples were kept for the measurement of serum creatinine, urea and PTH, and for bioassays with cultured rat astrocytes. The remaining sera were stored at -80°C.

Total parathyroidectomy (PTX) was performed as previously described (Klin et al., 1996; Michaud et al., 2006; Michaud et al., 2010). Briefly, surgical PTX was carried out under a surgical

microscope, without removal of the thyroid tissue. The success of the PTX was ascertained by a significant decrease of calcium after PTX. To avoid hypocalcemia, PTX animals were then supplemented with calcium by adding calcium gluconate to drinking water (control 5%; CRF 2.5%). Rats were then allowed to recover for a week before 5/6 nephrectomy. Control rats received sham surgery in the neck region.

Preparation of brain microsomes

Microsomes from cerebellum, cortex, hippocampus and remaining brain parenchyma or from whole brain were isolated as published by Cinti (Cinti et al., 1972; Leblond et al., 2000). The resulting pellet was suspended in either phosphate buffered saline containing 0.1 mM PMSF for Western blot analysis or in sucrose 0.25 M for CYP3A activity assessment. Samples were then sonicated on ice for 10 seconds to ensure homogeneity. Protein concentration was determined using the method of Lowry (Lowry et al., 1951), using bovine serum albumin as a reference protein. Aliquots were stored at -80°C up to Western blot analysis or CYP3A activity assessment.

Western blot analysis

Brain CYP450s levels were assessed by Western blot analysis following a previously described protocol (Leblond et al., 2002; Naud et al., 2007; Naud et al., 2008; Naud et al., 2011). Briefly, proteins were separated on 9% SDS-PAGE and transferred to nitrocellulose membrane. Non-specific proteins were blocked by incubating Western blot membranes in 5% skim milk in PBS. CYP450 proteins were detected using specific antibodies. CYP1A1/2 and CYP2E1 antibodies were from US Biologicals (Salem, MA), and CYP2C11, CYP2D and CYP3A antibodies were from Abcam (Cambridge, MA), Creative Biomart (Shirley, NY) and Millipore (Billerica, MA), respectively. Beta-Actin, used as a loading control, was detected using a mouse anti-chicken β -Actin (Neo-Markers, Fremont, CA). Secondary antibodies against mouse or rabbit IgG were from Sigma (St-Louis, MO). Antibodies were diluted in 0.5% skim milk and

membranes were washed with 0.1% Tween 20 in phosphate buffered saline. All blots were revealed using Lumi-light chemiluminescent reagents (Roche Diagnostics, Laval, Quebec, Canada). Each membrane was probed sequentially for a specific CYP isoform then for β -Actin.

Individual CYP450 protein levels were quantified by measuring the density of bands using an ImageQuant™ LAS 4000 software (GE Healthcare, Mississauga, Ontario, Canada). The measured density value was reported as a ratio over the expression of β -actin band intensity. Comparison of control and CRF group was always performed on the same membrane. The mean CYP/ β -Actin ratio for the control group was arbitrarily defined as 100% and all samples were expressed as a percentage of this value. Each blot was repeated in two independent experiments.

mRNA analysis

Total RNA was extracted from frozen tissue using Trizol reagent (Invitrogen, Burlington, Ontario, Canada) according to the manufacturer's protocol. RNA concentration was determined by measuring absorbance at a wavelength of 260 nm. One μ g of total RNA was used to prepare cDNA by reverse transcription using SuperScript® VILO™ cDNA Synthesis Kit from Invitrogen. Gene expressions were measured using appropriate TaqMan gene expression assays from Applied Biosystems (Carlsbad, CA). Table 1 shows the TaqMan gene expression assays used for the quantification of mRNA for each enzyme. Gene expression was determined using the $\Delta\Delta C_T$ method (Livak and Schmittgen, 2001) using β -actin expression as a reference.

Evaluation of CYP3A activity

In order to evaluate the metabolic activity of CYP3A in 200 μ g of microsomes prepared from whole brain extract of CTL, CTL-PTX, CRF and CRF-PTX rats, a selective fluorescent probe, 3-[(3,4-difluorobenzyl)oxy]-5,5-dimethyl-4-[4-methylsulfonyl]phenyl]furan-2(5H)-one (DFB) that is specifically metabolized by rat CYP3A to 3-hydroxy-5, 5-dimethyl-4-[4-

DMD # 70052

(methylsulfonyl) phenyl] furan-2(5H)-one (DFH) was used as previously reported (Nicoll-Griffith et al., 2004; Michaud et al., 2007; Michaud et al., 2008). DFH fluorescence was determined on a cytofluorometer (Cytofluor 4000/TR, Perspective Biosystems, Framingham, MA) using appropriate wavelength (excitation filter: 360/40 nm; emission filter: 460/40 nm). The standard curve was prepared with known dilutions of DFH.

Isolation and culture of rat astrocytes

To assess the impact of uremic serum or PTH on the ex-vivo expression of CYP450 in brain, we incubated rat astrocytes with serum from nephrectomized and PTX rats or with PTH and evaluated CYP3A protein expression. Rat astrocytes were isolated and cultured as previously described from unknown gender newborn rat pups (Booher and Sensenbrenner, 1972; Perriere et al., 2005; Naud et al., 2012a). When cells reached confluence, the standard culture medium was replaced with culture medium containing 10% serum from CTL, CTL-PTX, CRF or CRF-PTX rats (1 serum/flask) or medium containing 10% calf serum supplemented with 10 nM rat PTH (Rat synthetic 1-34 PTH, Sigma) or not. After 48 h of culture, cells were trypsinized, pelleted and homogenized in phosphate buffered saline containing 0.1 mM PMSF. Protein concentrations were determined using the Micro BCA Protein Assay Kit from Thermo Fisher Scientific (Rockford, IL). One hundred μ g of protein lysate was used for Western Blot analysis of CYP3A.

Other assays

Blood and urine chemistries were determined with an Architect C1600 clinical analyzer (Abbott, Saint-Laurent, QC, Canada). PTH serum levels were measured using the Rat intact PTH ELISA Kit (Alpco Diagnostics, Salem, NH), which measures intact 1-84 PTH. The lowest detectable level was 29 pg/ml.

Statistical analysis

DMD # 70052

Results are expressed as mean \pm SD. Statistical analysis was performed using SPSS software. Differences between groups were assessed using an unpaired Student's *t* test or an ANOVA test. Significant ANOVA was followed by a Scheffe *post hoc* comparison of groups. The threshold of significance was $p < 0.05$.

RESULTS

Biochemical parameters in control and CRF rats

Table 2 presents the biochemical parameters and body weight of control and CRF rats. As shown in the table, compared to control animals, CRF rats had higher levels of serum creatinine and urea, and lower creatinine clearance (reduced by 75%, $p < 0.001$). Also, compared to CTL animals, CRF rats had 10-fold higher levels of PTH ($p < 0.05$). There was no difference in body weight between control and CRF rats.

CYP450 expression in the dissected brain of control and CRF rats

First, we tested in control and CRF rats whether CRF could modify the brain CYP450 expression. Figure 1 shows the protein expression levels of various CYP450s in cerebellum, cortex, hippocampus and remaining brain tissue of control and CRF rats. Western blot analysis showed a 25 to 50% ($p < 0.05$) decrease in CYP1A, CYP2C11 and CYP3A protein levels in brain microsomes of CRF rats compared to control group, whereas CYP2D4 and CYP2E1 expression was found similar in both groups. Subdivision of the brain in 4 parts (cerebellum, cortex, hippocampus and remaining of the brain) showed that the effect of CRF on the expression of a specific CYP450 isoform was evenly distributed across the entire organ. Since we found no difference between various parts of the brain, the whole organ was used for subsequent analysis of the effects of PTH on CYP3A expression and activity. When we assessed the mRNA levels of individual CYP450 isoform in the brain of CRF rats, we did not find any significant modulation between groups (Supplemental Figure 1).

CYP3A protein expression in whole brain microsomes of CRF and parathyroidectomized CRF rats

To evaluate the role of PTH in the *in vivo* modulation of CYP3A, we surgically removed

the parathyroid glands 7 days prior to the first nephrectomy, thus preventing secondary hyperparathyroidism. Table 3 presents the body weight and biochemical characteristics of parathyroidectomized rats. Compared to control animals, CRF rats had significantly higher levels of PTH ($p < 0.05$), while in PTX animals PTH levels were below the lowest detectable concentration and were unaffected by CRF.

CYP3A protein expression was measured in whole brain microsomes purified from CTL, CRF, CTL-PTX and CRF-PTX rats. As shown in Figure 2 there was a significant decrease of CYP3A protein expression in whole brain microsomes isolated from CRF rats compared to CTL, and PTX treatment prevented the CYP3A protein level reduction in CRF rats suggesting that PTX prevents the CYP3A downregulation induced by CRF. No significant modulation of mRNA expression was observed in all groups (Supplemental Figure 2).

CYP3A activity in whole brain microsomes of CRF rats

To evaluate if CRF affected CYP3A activity as well, we assessed *in vitro*, using fluorescently labeled DFB, the enzymatic activity of CYP3A. DFB is converted into DFH by CYP3A and fluorescence intensity of DFH is readily measured on a cytofluorometer. To this end, we measured the conversion of DFB into DFH by CYP3A in brain microsomes isolated from CTL, CRF, CRF-PTX, and CTL-PTX rats. As shown in Figure 3, brain microsomes purified from rats with CRF produced 50% less DFH ($p < 0.05$) compared to CTL, CTL-PTX and CRF-PTX rats, suggesting a decrease in CYP3A activity by CRF is likely due to impact of parathyroid-derived factor such as PTH.

CYP3A expression in astrocytes cultured with serum from CTL, CRF and PTX rats

To confirm the possible role of PTH present in uremic serum of CRF rats in the *in vivo* downregulation of brain CYP3A, we evaluated the effects of serum from control and CRF rats on

DMD # 70052

cultured astrocytes isolated from normal rats. We incubated normal rat astrocytes for 48 h with serum from control, CTL-PTX, CRF or CRF-PTX animals. As shown in Figure 4, serum from CRF rats reduced CYP3A expression by 30% ($p < 0.05$), whereas serum from CRF-PTX rats had no effects on CYP3A levels in rat astrocytes.

CYP3A expression in astrocytes cultured with PTH

To provide direct evidence for role of PTH in modulating CYP3A levels in astrocytes, we cultured astrocytes isolated from normal rats in the presence of purified PTH. Results depicted in Figure 5 show that incubation of astrocytes with 10 nM PTH decreased CYP3A by 30% ($p < 0.05$) compared to control astrocyte culture lacking PTH, suggesting that CRF in rats may result in high serum PTH and that this could be an important factor in the downregulation of brain CYP3A in CRF rats.

DISCUSSION

Brain cytochrome P450 plays an important role in the local metabolism of endogenous and exogenous compounds. Alteration in brain cytochrome P450 levels could significantly affect normal brain function or lead to local toxicity of drugs. It is a well recognized fact that CRF patients are subject to elevated drug toxicity and that CYP450 metabolism is impaired. The purpose of this study was to investigate the effect of CRF on brain CYP450 in whole brain or specific regions of brain of rats and the involvement of PTH. To address this, we measured CYP450 in cerebellum, cortex, hippocampus and remaining brain tissue from CRF and CTL rats. To investigate the role of PTH, we measured CYP3A in whole brain microsomes derived from CRF, CRF-PTX, CTL-PTX and CTL rats. This study demonstrates that CRF affects the expression and activity of specific isoforms of brain CYP450s (CYP3A, 2C11 and 1A) and that PTH could be a mediator of this modulation.

Modulation of CYP450 described in this study is similar to that observed in the liver and intestine of CRF rats (Leblond et al., 2001; Leblond et al., 2002). Indeed, in the different brain regions, we observed downregulations of CYP3A, CYP2C11 and CYP1A protein expression, but no modulation of CYP2D4 and CYP2E1 (Figure 1). In rat liver and intestine, endogenous factors were shown to be responsible for the CYP450 impairment. Furthermore, in the liver, PTH was identified as the major mediator for the CYP3A modulation (Michaud et al., 2006; Michaud et al., 2010).

To further develop our hypothesis that CRF may affect CYP450 levels in brain via altered PTH levels, we first evaluated CYP3A expression in whole brain microsomes from rats that underwent total parathyroidectomy. Whole brain microsomes were used because CYP450 modulations had proven to be similar in all brain regions (Figure 1), and because using whole brain allowed for a higher sample yield. As shown in Table 3, PTX animals had undetectable PTH levels,

while CRF animals had significantly increased levels compared to CTL animals. Also, CRF and CRF-PTX animals had similar renal impairment as shown by their respective creatinine clearance rate. Figure 2 shows that, similarly to that observed in rat liver (Michaud et al., 2006), parathyroidectomy abrogated the downregulation of CYP3A protein in whole brain microsomes from CRF animals. PTX alone had no impact on CYP3A expression, as shown in the CTL-PTX group. In vitro, sera from CRF rats decreased CYP3A in normal rat astrocytes, whereas sera from CTL and PTX rats did not (Figure 4). Also, incubation of astrocytes with 10 nM purified PTH for 48 h led to a significant decrease in the protein expression of CYP3A in normal astrocytes (Figure 5) supporting the hypothesis that PTH could be a factor in the downregulation of CYP3A protein expression in the rat brain in CRF as was previously shown in the liver (Leblond et al., 2001; Leblond et al., 2002; Michaud et al., 2006).

Finally, we showed that not only CYP3A expression but also its enzymatic activity are reduced in CRF rats whole brain microsomes (Figure 3). CYP3A enzymatic activity was assessed in whole brain microsomes from CRF, CTL, CRF-PTX and CTL-PTX rats by the in vitro conversion of DFB to DFH. This method was previously shown to be specific to rat CYP3A (Michaud et al., 2007). This mimics what was previously observed in the liver (Michaud et al., 2006).

Our results suggest that PTH may be a mediator in the downregulation of brain CYP450 by CRF in vitro and in vivo. There are two PTH receptors expressed in the brain: PTH1R and PTH2R, the latter having the highest expression (Goswami et al., 2014). Both receptors, in response to PTH binding, can increase cAMP production and $[Ca^{2+}]_i$ and this can lead to activation of protein kinase A (PKA) and phosphorylation of proteins, including CYP450 (Swarthout et al., 2002; Bisello et al., 2004). Phosphorylation of CYP450 by PKA leads to a decrease in metabolic activity (Pyerin et al., 1987; Jansson et al., 1990). It can also lead to a downregulation of CYP450 gene expression (Sidhu and Omiecinski, 1995; Galisteo et al., 1999). Thus, there is a possibility that the PTH receptors in

the brain are stimulated by the increased systemic PTH levels which may in turn, lead to CYP450 downregulation in CRF.

A major difference exists, however, between the previously cited reports in the liver and intestine (Leblond et al., 2001; Leblond et al., 2002; Michaud et al., 2006) and our results: we found no effect of CRF on mRNA expression for the different CYP450 enzymes. This suggests a different pathway for the regulation of liver and brain CYP450 in CRF. While significant progress has been made in our understanding of regulation of CYP450 in brain, and different regions of brain, (Meyer et al., 2007; Miksys and Tyndale, 2013), our data indicate a possible different mode of CYP450 regulation in brain compared to liver. Our results point towards post-translational regulation, but the exact mechanisms involved remains to be identified.

This study clearly shows that CRF affects the expression of some CYP450 isoforms in brain. These enzymes have endogenous and exogenous local functions. Whether altered CYP450 levels could lead to local drug toxicity or could affect normal brain metabolism remains to be studied.

DMD # 70052

AUTHORSHIP CONTRIBUTIONS

Participated in research design: Naud, Harding, Pichette

Conducted experiments: Naud, Harding, Lamarche, Beauchemin, Leblond

Performed data analysis: Naud, Lamarche, Leblond, Pichette

Wrote or contributed to the writing of the manuscript: Naud, Leblond, Pichette

REFERENCES

- Bisello A, Manen D, Pierroz DD, Usdin TB, Rizzoli R, and Ferrari SL (2004) Agonist-specific regulation of parathyroid hormone (PTH) receptor type 2 activity: structural and functional analysis of PTH- and tuberoinfundibular peptide (TIP) 39-stimulated desensitization and internalization. *Mol Endocrinol* 18:1486-1498.
- Booher J and Sensenbrenner M (1972) Growth and cultivation of dissociated neurons and glial cells from embryonic chick, rat and human brain in flask cultures. *Neurobiology* 2:97-105.
- Cinti DL, Moldeus P, and Schenkman JB (1972) Kinetic parameters of drug-metabolizing enzymes in Ca²⁺-sedimented microsomes from rat liver. *Biochem Pharmacol* 21:3249-3256.
- Galisteo M, Marc N, Fautrel A, Guillouzo A, Corcos L, and Lagadic-Gossmann D (1999) Involvement of cyclic nucleotide- and calcium-regulated pathways in phenobarbital-induced cytochrome P-450 3A expression in mouse primary hepatocytes. *J Pharmacol Exp Ther* 290:1270-1277.
- Goswami R, Millo T, Mishra S, Das M, Kapoor M, Tomar N, Saha S, Roy TS, and Sreenivas V (2014) Expression of osteogenic molecules in the caudate nucleus and gray matter and their potential relevance for Basal Ganglia calcification in hypoparathyroidism. *J Clin Endocrinol Metab* 99:1741-1748.
- Imaoka S, Hashizume T, and Funae Y (2005) Localization of rat cytochrome P450 in various tissues and comparison of arachidonic acid metabolism by rat P450 with that by human P450 orthologs. *Drug Metab Pharmacokinet* 20:478-484.
- Jansson I, Curti M, Epstein PM, Peterson JA, and Schenkman JB (1990) Relationship between phosphorylation and cytochrome P450 destruction. *Arch Biochem Biophys* 283:285-292.
- Klin M, Smogorzewski M, Ni Z, Zhang G, and Massry SG (1996) Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. *J Clin Invest* 97:2167-2173.
- Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, and Pichette V (2001) Downregulation of hepatic cytochrome P450 in chronic renal failure. *J Am Soc Nephrol* 12:326-332.
- Leblond FA, Giroux L, Villeneuve JP, and Pichette V (2000) Decreased in vivo metabolism of drugs in chronic renal failure. *Drug Metab Dispos* 28:1317-1320.
- Leblond FA, Petrucci M, Dube P, Bernier G, Bonnardeaux A, and Pichette V (2002) Downregulation of intestinal cytochrome p450 in chronic renal failure. *J Am Soc Nephrol* 13:1579-1585.
- Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25:402-408.
- Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the folin phenol reagent. *J Biol Chem* 193:265-275.
- Meyer RP, Gehlhaus M, Knoth R, and Volk B (2007) Expression and function of cytochrome p450 in brain drug metabolism. *Curr Drug Metab* 8:297-306.
- Michaud J, Leblond FA, Naud J, Boisvert C, Desbiens K, Nicoll-Griffith DA, and Pichette V (2007) Use of a fluorescent substrate for the selective quantification of rat CYP3A in the liver and the intestine. *J Pharmacol Toxicol Methods* 55:209-213. Epub 2006 Aug 2004.

- Michaud J, Naud J, Chouinard J, Desy F, Leblond FA, Desbiens K, Bonnardeaux A, and Pichette V (2006) Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. *J Am Soc Nephrol* 17:3041-3048. Epub 2006 Oct 3044.
- Michaud J, Naud J, Ouimet D, Demers C, Petit JL, Leblond FA, Bonnardeaux A, Gascon-Barre M, and Pichette V (2010) Reduced hepatic synthesis of calcidiol in uremia. *J Am Soc Nephrol* 21:1488-1497.
- Michaud J, Nolin TD, Naud J, Dani M, Lafrance JP, Leblond FA, Himmelfarb J, and Pichette V (2008) Effect of hemodialysis on hepatic cytochrome P450 functional expression. *J Pharmacol Sci* 108:157-163. Epub 2008 Oct 2009.
- Miksys S and Tyndale RF (2013) Cytochrome P450-mediated drug metabolism in the brain. *J Psychiatry Neurosci* 38:152-163.
- Miksys SL and Tyndale RF (2002) Drug-metabolizing cytochrome P450s in the brain. *J Psychiatry Neurosci* 27:406-415.
- Morse DC, Stein AP, Thomas PE, and Lowndes HE (1998) Distribution and induction of cytochrome P450 1A1 and 1A2 in rat brain. *Toxicol Appl Pharmacol* 152:232-239.
- Naud J, Laurin LP, Michaud J, Beauchemin S, Leblond FA, and Pichette V (2012a) Effects of chronic renal failure on brain drug transporters in rats. *Drug Metab Dispos* 40:39-46.
- Naud J, Michaud J, Beauchemin S, Hebert MJ, Roger M, Lefrancois S, Leblond FA, and Pichette V (2011) Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. *Drug Metab Dispos* 39:1363-1369.
- Naud J, Michaud J, Boisvert C, Desbiens K, Leblond FA, Mitchell A, Jones C, Bonnardeaux A, and Pichette V (2007) Down-regulation of intestinal drug transporters in chronic renal failure in rats. *J Pharmacol Exp Ther* 320:978-985. Epub 2006 Nov 2029.
- Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, and Pichette V (2008) Effects of chronic renal failure on liver drug transporters. *Drug Metab Dispos* 36:124-128. Epub 2007 Oct 2016.
- Naud J, Nolin TD, Leblond FA, and Pichette V (2012b) Current understanding of drug disposition in kidney disease. *J Clin Pharmacol* 52:10S-22S.
- Nicoll-Griffith DA, Chauret N, Houle R, Day SH, D'Antoni M, and Silva JM (2004) Use of a benzyloxy-substituted lactone cyclooxygenase-2 inhibitor as a selective fluorescent probe for CYP3A activity in primary cultured rat and human hepatocytes. *Drug Metabolism and Disposition* 32:1509-1515.
- Perriere N, Demeuse P, Garcia E, Regina A, Debray M, Andreux JP, Couvreur P, Scherrmann JM, Temsamani J, Couraud PO, Deli MA, and Roux F (2005) Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. *J Neurochem* 93:279-289.
- Pyerin W, Horn F, and Taniguchi H (1987) Posttranslational modifications of the cytochrome P-450 monooxygenase system. *J Cancer Res Clin Oncol* 113:155-159.
- Sidhu JS and Omiecinski CJ (1995) cAMP-associated inhibition of phenobarbital-inducible cytochrome P450 gene expression in primary rat hepatocyte cultures. *J Biol Chem* 270:12762-12773.
- Swarthout JT, D'Alonzo RC, Selvamurugan N, and Partridge NC (2002) Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. *Gene* 282:1-17.

DMD # 70052

Yadav S, Dhawan A, Seth PK, Singh RL, and Parmar D (2006) Cytochrome P4503A: evidence for mRNA expression and catalytic activity in rat brain. *Mol Cell Biochem* 287:91-99.

DMD # 70052

FOOTNOTES

This work was financed La Fondation Hôpital Maisonneuve-Rosemont (La néphrologie et son Impact). V Pichette is supported by a career award from FRSQ.

Reprint requests should be sent to: Vincent Pichette MD Ph.D.
Centre de recherche de l'hôpital Maisonneuve-Rosemont
5415 boul. de l'Assomption, Montréal, Québec, Canada
H1T 2M4

Legend of figures

Figure 1: Protein expression of various CYP450s in the dissected brain of CRF rats. A. Protein bands are expressed in densitometry units. The densitometry units measured for CYP450s in control (CTL, n=12) and chronic renal failure (CRF, n=13) rats were standardized by dividing them by the value obtained for β -actin. The standardized densitometry units of control rats were arbitrarily defined as 100% and are represented by the dotted line. Graphic shows the mean expression in CRF rats expressed as percent of controls \pm SD in cerebellum, cortex, hippocampus and remaining brain tissue. * p <0.05, ** p <0.01 compared to control rats. **B.** Typical blot pictures are shown for each CYP450 isoform and the corresponding β -actin in each part of the brain.

Figure 2: CYP3A protein expression in whole brain microsomes of CRF-PTX rats. Protein bands are expressed in densitometry units. The densitometry units measured for CYP3A in control (CTL, n=13), parathyroidectomized controls (CTL-PTX, n=8), chronic renal failure (CRF, n=13) and parathyroidectomized CRF (CRF-PTX, n=11) rats were standardized by dividing them by the value obtained for β -actin. The mean relative quantity of control rats was arbitrarily defined as 100%. Graphic shows the mean expression in rats expressed as percent of controls \pm SD. * p <0.05 compared to control rats. Typical blot pictures are shown for CYP3A and the corresponding β -actin in each group.

Figure 3: CYP3A activity in whole brain microsomes of CRF rats.

CYP3A activity was measured by using DFB as a substrate and measuring its conversion to DFH in control (CTL, n=13), parathyroidectomized controls (CTL-PTX, n=8), parathyroidectomized CRF (CRF-PTX, n=11) rats and chronic renal failure (CRF, n=13). The mean relative DFH

production in control rats was arbitrarily defined as 100%. Graphic shows the mean DFH production in rats expressed as percent of controls \pm SD. * p <0.05 compared to control rats.

Figure 4: CYP3A protein expression in astrocytes incubated with rat serum Protein bands are expressed in densitometry units. The densitometry units measured for CYP3A in astrocytes incubated for 48 h with serum from control (CTL, $n=5$), chronic renal failure (CRF, $n=5$), parathyroidectomized controls (CTL-PTX, $n=4$), and parathyroidectomized CRF (CRF-PTX, $n=4$) rats were standardized by dividing them by the value obtained for β -actin. The standardized densitometry units of control condition were arbitrarily defined as 100%. Graphic shows the mean expression in rats expressed as percent of controls \pm SD. * p <0.05 compared to serum from control rats. Typical blot pictures are shown for CYP3A and the corresponding β -actin in each group.

Figure 5: CYP3A protein expression in astrocytes incubated with rat PTH Protein bands are expressed in densitometry units. The densitometry units measured for CYP3A in astrocytes incubated for 48 h without PTH (No PTH, $n=4$) and with 10 nM PTH (PTH, $n=4$) rats were standardized by dividing them by the value obtained for β -actin. The standardized densitometry units of No PTH were arbitrarily defined as 100%. Graphic shows the mean expression in rats expressed as percent of No PTH \pm SD. * p <0.05 compared to No PTH. Typical blot pictures are shown for CYP3A and the corresponding β -actin in each group.

Tables and figures

Table 1. TaqMan gene expression assays used for Real-time PCR

Gene	TaqMan Gene Expression Assay
<i>Actb</i>	Rn00667869_m1
<i>CYP1A1</i>	Rn00487218_m1
<i>CYP2C11</i>	Rn00569868_m1
<i>CYP2D1</i>	Rn01775090_mH
<i>CYP2E1</i>	Rn01759587_m1
<i>CYP3A1</i>	Rn03062228_m1

Table 2. Characteristics of control and CRF rats

Group		CTL	CRF
Rats (n)		12	13
Body weight	g	362.8 ± 25.7	371.5 ± 75.9
Serum creatinine	μmol/L	59.4 ± 3.1	197.9 ± 85.9 ^a
Creatinine clearance^b	μl/100g/min	244.0 ± 89.9	65.5 ± 27.3 ^a
PTH (n)	pg/ml	121.7 ± 26.3	1526.8 ± 568.9 ^a

^a: $p < 0.05$ vs. Control group

Data are the mean ± SD. Measurements were made at the time of sacrifice. Twenty-four hour urinary collection was begun the day before. Blood urea and creatinine, and urine creatinine were determined with an Architect C1600 clinical analyzer (Abbott, Saint-Laurent, QC, Canada).


Table 3. Characteristics of parathyroidectomized, control and CRF rats

		Nephrectomy			
		(-)		(+))	
PTX		(-)	(+)	(-)	(+)
Group		CTL	CTL-PTX	CRF	CRF-PTX
Rats (n)		13	8	13	11
Body weight	g	381.2 ± 20.9	432.0 ± 30.5 ^a	317.9 ± 60.4 ^a	392.0 ± 43.0
Serum creatinine	µmol/L	63.3 ± 5.0	66.3 ± 2.4	230.5 ± 74.9 ^a	186.4 ± 61.1 ^a
Creatinine clearance^b	µl/100g/min	288.4 ± 52.9	239.4 ± 36.1	56.6 ± 38.1 ^a	76.0 ± 26.8 ^a
PTH (n)	pg/ml	113.6 ± 36.8	<29 ^a	1304.1 ± 914.7 ^a	<29 ^a

^a: p<0.05 vs. Control group

^b: Data are the mean ± SD. Measurements were made at the time of sacrifice. Twenty-four hour urinary collection was begun the day before. Blood urea and creatinine, and urine creatinine were determined with an Architect C1600 clinical analyzer (Abbott, Saint-Laurent, QC, Canada).

Figure 1 A



B




Figure 2




Figure 3




Figure 4




Figure 5

